Clinical Analysis of the Influence of Using the Skin Care Products on the Diaper Area in Comparison with Using a Cotton Wool Cloth, Moistened with Clear Water on the Skin Physiology of the Newborns from the 1st Day to the 4th Week of Life
Standardized Skin Care Regimen in the Diaper Area: a Prospective, Randomized Clinical Study on Skin Barrier Function and Epidermal IL-1α
1 other identifier
observational
44
0 countries
N/A
Brief Summary
Study design: The purpose of the present study is to analyse of the influence of the application of the skin care products on the diaper area (Factor A) and the application of a cotton wool cloth, moistened with clear water on the diaper area (Faktor B) on the skin barrier function of the newborns during the first four weeks. Additionally, the microbiological colonisation of the skin will be observed. After four weeks all infants in both groups will obtain wet wipe and after 8 weeks a facultative measurement will be performed. Primary and secondary end points: In the present study, as a primary end point TEWL on the buttock was chosen, because the significant difference between the infants who were bathed and washed in the previous study was found. Secondary end points are the TEWL on the other measuring points, pH-value and SCH. Additionally, secondary end points are the D-Squame method and the cytokine measurement with Sebutapes. Hypotheses: The intention of the study is to evaluate, whether the using of wet wipe on the diaper area has an influence on the TEWL of the newborns. The following hypotheses are present below: H0 (Null hypothesis): The TEWL is indistinguishable between infants who get cleaned with wet wipe on the diaper area and infants who get cleaned with a cotton wool cloth, moistened with clear water on the diaper area, i.e. TEWL clear water is equal TEWL wet wipe against H1 (Alternative hypothesis - bilateral): The TEWL is distinguishable between infants who get cleaned with wet wipe on the diaper area and infants who get cleaned with a cotton wool cloth, moistened with clear water on the diaper area, i.e. TEWL clear water is not equal TEWL wet wipe
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2007
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2007
CompletedFirst Submitted
Initial submission to the registry
May 26, 2010
CompletedFirst Posted
Study publicly available on registry
May 27, 2010
CompletedFebruary 13, 2025
May 1, 2007
5 months
May 26, 2010
February 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
TEWL
TEWL= transepidermal waterloss
second day of life, 14 day of life and 28 day of life
Secondary Outcomes (5)
pH
second day of life, 14 day of life and 28 day of life
SCH
2nd, 14th and 28th day of life
D-Squame
2nd, 14th and 28th day of life
Interleukin-1α
2nd, 14th and 28th day of life
microbiological colonisation
2nd, 14th and 28th day of life
Study Arms (2)
BW= using baby wipes and CW= using cotton wool
wet wipe, cotton wool
Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.
Eligibility Criteria
group of 40 healthy full-term newborn babies
You may qualify if:
- Male and female term newborns from 37 completed weeks of gestation, age ≤ 48 hours
- Written informed parental consent
You may not qualify if:
- Any critically ill term newborn, i.e. septic infants, infants born with serious congenital malformation/defects, asphyxia, hydronephrosis, severe intracranial hemorrhage
- Newborns with known immunodeficiency
- Newborns with pre-existing skin disease with eruptions covering more than 50% of body surface i.e. congenital ichthyosis, congenital candidiasis
- Newborn has relevant skin maceration, which influence the measurements or is communicable i.e. urticaria or herpes
- Any acutely or chronically ill newborn with temperatures below 35°C or above 40°C
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kathrin HILLMANNlead
- Johnson & Johnson GmbHcollaborator
Study Officials
- PRINCIPAL INVESTIGATOR
Ulrike Blume-Peytavi, MD, PhD
Department of Dermatology, Charite-Universitätsmedizin, Berlin
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Dr. med.
Study Record Dates
First Submitted
May 26, 2010
First Posted
May 27, 2010
Study Start
May 1, 2007
Primary Completion
October 1, 2007
Study Completion
October 1, 2007
Last Updated
February 13, 2025
Record last verified: 2007-05